ArticleFrontiers in pharmacology2025
Persistent benefit of pharmacogenomic testing on initial remission and response rates in patients with major depressive disorder.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- The evolving landscape of pharmacogenomics: Current achievements and future directions.Pharmacological reviews · 2026Review
- Implementation of preemptive pharmacogenetic testing: progress, puzzles and priorities from an implementation science perspective.Frontiers in pharmacology · 2026Review
- Risk-managed antidepressant prescribing in primary care mental health: what pharmacogenetics can (and cannot) deliver.Frontiers in medicine · 2026Article
- Precision medicine decision-making under pharmacogenomics in nursing: realizing value from limited evidence to scaled clinical pathways.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In patients with major depressive disorder (MDD), achieving remission and/or response may take many months because of the lengthy trial-and-error process often needed to identify effective medication. Pharmacogenomic testing is a prescribing tool that has been shown to improve remission and response rates for MDD patients, but data describing its impact over time is limited. The objective of this study was to determine whether pharmacogenomic-guided treatment increases the rate of remission and response over time in patients with MDD, and if so, to assess the persistence of that effect. Methods: This study was a prespecified Results: 1,764 (90.7%) of the 1,944 veterans who participated in the PRIME Care trial had sufficient visit data to be included in this analysis. Patients who received pharmacogenomic-guided treatment had higher rates of remission (HR [95% CI] = 1.27 [1.05, 1.53]; p = 0.015) and response (HR [95% CI] = 1.21 [1.05, 1.40]; p = 0.010) at any time relative to patients receiving usual care. Schoenfeld residuals tests were not statistically significant for remission (p = 0.931) or response (p = 0.112), providing no evidence that the benefit due to pharmacogenomic-guided treatment changed over the 24-week period. Conclusion: Pharmacogenomic-guided treatment led to faster initial remission and response in patients with MDD, and this benefit persisted over 6 months with no evidence of changing over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.